18 - 19 November 2021, virtual, broadcast from Munich, Germany

Scientific Programme

Scientific programme of the virtual CVOT Summit on 18-19 November 2021

Thursday, 18 November 2021
Virtual
16:30 - 16:40 CET
Welcome and introductionSchnell O (Munich, Germany)
16:40 – 18:40 CET
The Guideline Workshop – A global initiative for guideline acceleration and harmonization in diabetes Chair: Marx N (Aachen, Germany), Rodbard H (Rockville, US)
16:40 – 17:00
Living evidence and guidance in diabetes – The future of guideline creation?Vandvik PO (Oslo, Norway)
17:00 – 17:20
CGM in diabetes: Which studies designs are relevant for living guidelines? Battelino T (Ljubljana, Slovenia)
17:20 – 17:40
Pilot projects of the Guideline Workshop – Key learnings for guidelines in diabetes and CVD Marx N (Aachen, Germany)
17:40 – 18:00
Innovative strategies for the creation of CKD GuidelinesBrosius F (Tucson, USA)
18:00 – 18:20
COVID-19 and diabetes: Guidelines and learnings from DARE Kosiborod M (Kansas City, USA)
18:20 – 18:40
Discussion
18:40 – 19:00 CET
Break
19:00 – 20:20 CET
Insulins and glycemic outcomes Chair: Schumm-Draeger P (Munich, Germany), Lalic N (Belgrade, Serbia)
19:00 – 19:20
Understanding biosimilar insulinsVilsbøll T (Copenhagen, Denmark)
19:20 – 19:40
Insulin treatment: A perspective on new outcomesForst T (Mannheim, Germany)
19:40 – 20:00
Novel glucose metrics - Towards accepted outcomes in diabetes Bergenstal R (Minneapolis USA)
20:00 – 20:20
Discussion
Friday, 19 November 2021
Virtual
08:30 – 10:00 CET
Cardiovascular management in diabetes: Recent considerationsChair: Ji L (Beijing, China), Standl E (Munich, Germany)
08:30 – 08:45
Primary care: Screening and diagnosis for an optimized diabetes management Cos Claramunt FX (Barcelona, Spain)
08:45 – 09:00
Cardiorenal risk in type 2 diabetes - Should we treat to prevent? Itzhak B (Haifa, Israel)
09:00 – 09:15
Cardiovascular prevention in diabetes: Current strategies with AspirineSantilli F (Chieti, Italy)
09:15 – 09:30
Diabetes therapies: Mechanisms of action in the heartCarr R (London, UK)
09:30 – 10:00
Discussion
10:00 – 10:30 CET
Break
10:30 – 11:30 CET
Heart failure: New Guidelines and treatment strategies Chair: Ceriello A (Milano, Italy), Lehrke M (Aachen, Germany)
10:30 – 10:50
ESC heart failure Guidelines: What´s new? Implementation in clinical practice Rosano GP (Padova, Italy)
10:50 – 11:10
SGLT-2 inhibition in HFrEF and HFpEF – New outcomesBoehm M (Homburg/Saar, Germany)
11:10 – 11:30
Discussion
11:30 – 12:30 CET
Diabetic kidney disease: MRAs – Where are we moving? Chair: Rydén L (Stockholm, Sweden), Heerspink H (Groningen, Netherlands)
11:30 – 11:50
Finerenone - New outcomes in chronic kidney disease and type 2 diabetes Rossing P (Copenhagen, Denmark)
11:50 – 12:10
Future perspectives of MRAs Heerspink H (Groningen, Netherlands)
12:10 – 12:30
Discussion
12:30 – 13:00 CET
Break
13:00 – 14:00 CET
Recent clinical outcomes in chronic kidney disease Chair: Heerspink H (Groningen, Netherlands), Wanner C (Wuerzburg, Germany)
13:00 – 13:20
One year on from DAPA-CKDHeerspink H (Groningen, Netherlands)
13:20 – 13:40
Renal outcomes with GLP-1 RAs Giorgino F (Bari, Italy)
13:40 – 14:00
Discussion
14:00 – 14:30 CET
Discussion round with expertsChair: Giorgino F (Bari, Italy), Rydén L (Stockholm, Sweden)
14:00 – 14:30
SGLT2 inhibitors, MRAs and GLP1-RAs: The next decadeBoehm M (Homburg/Saar, Germany)
Ceriello A (Milano, Italy)
Giorgino F (Bari, Italy)
Heerspink H (Groningen, Netherlands)
Lehrke M (Aachen, Germany)
Rosano G (Padova, Italy)
Rossing P (Copenhagen, Denmark)
Wanner C (Wuerzburg, Germany)
14:30 – 15:00 CET
Break
15:00 – 16:15 CET
Obesity and NASH: Where are we moving with GLP1-RAs and dual GIP/GLP1-RAs?Chair: Wysham C (Rockwood, US), Blueher M (Leipzig, Germany)
15:00 – 15:20
CVOTs in GLP1-RA: The power of individual endpointsNauck M (Bochum, Germany)
15:20 – 15:40
Dual GIP/GLP1-RAs – Outcomes and future perspectivesWysham C (Rockwood, US)
15:40 – 16:00
Obesity and NASH: Novel treatment optionsBlueher M (Leipzig, Germany)
16:00 – 16:15
Discussion
16:15 – 17:15 CET
Industry´s perspective - panel discussion
17:15 – 18:15 CET
Oral presentationsChair: Standl E (Munich, Germany)
Healthy China program – early diabetic kidney disease screening Gu W-J et al. (Beijing, China)
Impact on diagnosis and management of diabetic kidney disease in real life clinical practiceSchultes B et al. (St. Gallen, Switzerland)
Cardiovascular pathology in patients with non-alcoholic fatty liver disease with overweight and obesityPivtorak K (Vinnytsia, Ukraine)
Autonomic neuropathy: impact on carbohydrate metabolism and therapeutical challenges Kempler P et al. (Budapest, Hungary)
Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes – data from a randomized, placebo-controlled studyRau M et al. (Aachen, Germany)
Updated meta-analysis of cardiovascular outcome trials evaluating cardiovascular efficacy of glucagon-like peptide-1 receptor agonistsPatoulias D et al. (Thessaloniki, Greece)
18:15 – 18:45 CET
Abstract awards and closingSchnell O (Munich, Germany)